Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Keep selling, I'm buying

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Oct 22, 2021 7:29pm

183 Views

Post# 34039745

RE:Keep selling, I'm buying

Yes I trust you

mstrmnd (163)

April 26, 2021 - 03:21 PM

300 Reads

Post# 33068266

T-minus: Last Call

Getting ready to blow!

Don't miss out - last call

GLTA!

mstrmnd wrote: ATE.TO
Market Cap: $45M
Cash: $60M
Assets (including unified IP):
1. Otenaproxesul - target $1B sale
2. ATB-352
3. ATB-429
4. ATB-340
5. Other patents to drug pipeline

Fully funded to 2024, I'm increasing my position, lets go Don Haut!!

GLTA